EUCTR2010-022077-33-IT进行中（未招募）1 期
Phase II, open label, study of primary chemotherapy with Bevacizumab in association with carboplatin, paclitaxel in early and locally advanced triple negative (ER, PgR and HER2 negative) breast cancer - CaPaBe
AZIENDA OSPEDALIERA POLICLINICO DI MODENA0 个研究点开始时间: 2010年12月27日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •?Age ?18 years and <75 years
- •?Pre- or post-menopausal women with histologically proven, previously untreated, primary breast cancer stage II-IIIC
- •?ER (< 1% by IHC) and PgR (< 1% by IHC) negative
- •?HER2/neu not overexpressed (Fish negative, or IHC score 0-1+ , or IHC score 2+ AND FISH negative)
- •?Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as ?20 mm with conventional techniques
- •?Availability of tumor tissue suitable for biological and molecular examination before starting primary treatment
- •?ECOG performance status < 2 (Karnofsky ?60%)
- •?Normal organ and marrow function (leukocytes ? 3,000/uL, absolute neutrophil count ?1,500/ul, platelets ?100,000/uL, total bilirubin within normal institutional limits, AST(S-GOT)/ALT(S-GPT) <2.5 x institutional upper limit of normal, creatinine within normal institutional limits or creatinine clearance ?60 mL/min
- •?Cardiac ejection fraction within normal institutional limits defined as LVEF not below the institutional lower limit of normal by either echocardiogram or MUGA
- •?Urine dipstick for proteinuria <2+. Patient discovered to have >2+ proteinuria on dipstick urinalysis at baseline, should undergo a 24-hour urine collection and must demostrate < 1 g of protein/24hr
- •?Women of child-bearing potential must agree to use adequate contraception prior to study entry and for the duration of study participation
- •?Ability to understand and the willingness to sign a written informed consent document.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •?Presence of distant metastases
- •?Patients receiving any others investigational agents
- •?Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgery during the course of the study treatment, or minor surgical procedures within 24 hours prior to randomization
- •?History of allergic reactions attributed to compounds of similar chemical or biologic composition used in the study
- •?Uncontrolled intercurrent illness including, but not limited, to uncontrolled hypertension (systolic >150 mmHg and/or diastolic >100 mmHg)ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, symptomatic peripheral neuropathy, or psychiatric illness/social situations that would limit compliance with study requirements
- •?Serious non-healing wound, peptic ulcer, or bone fracture
- •?History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months of randomization
- •?Pregnant women are excluded from this study because of the potential for teratogenic or abortifacient effects of agents included in this trial. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother, breastfeeding must be discontinued.
研究者
相似试验
进行中（未招募）
不适用
Randomized phase II trial of first line chemoterapy Docetaxel given in combination with Cisplatin for 6 cycles or Docetaxel given in combination with Cisplatin for 3 cycles followed by Docetaxel alone for 3 cycles in patients with advanced non-small-cell lung cancer. - NDPatients with advanced non-small-cell lung cancerMedDRA version: 9.1Level: LLTClassification code 10026532Term: Malignant neoplasm of thoraxEUCTR2007-002625-77-ITFONDAZIONE ISTITUTO SAN RAFFAELE-G.GIGLIO
已完成
不适用
Phase II trial as new adjuvant chemotherapy regimen for capecitabine in stage II and III colorectal cancer.StageII(high risk) and stageIIIa resectable colorectal cancerJPRN-UMIN000012813Tsukasa Hotta25
进行中（未招募）
不适用
TMC114-TiDP29-C228 – A safety study to evaluate the antiviral activity of darunavir (DRV) in combination with ritonavir (rtv) in HIV 1 infected children from 3 years to below 6 years of ageThe purpose of this Phase II trial is to evaluate the pharmacokinetics (blood levels), safety and antiviral activity to support dose recommendations by body weight of darunavir with low-dose ritonavir (DRV/rtv), in combination with other antiretroviral drugs (ARVs), in treatment-experienced HIV 1 infected children aged from 3 years to < 6 years and weighing between 10 kg and < 20 kg .MedDRA version: 16.1Level: LLTClassification code 10020192Term: HIV-1System Organ Class: 100000004862EUCTR2008-004630-25-Outside-EU/EEATibotec Pharmaceuticals24
进行中（未招募）
不适用
A safety study to evaluate the antiviral activity of darunavir in combination with ritonavir in HIV 1 infected adolescents between 12 and 18 years of age who have not received previous treatment with antiretroviral drugsHIV-1MedDRA version: 14.1Level: PTClassification code 10020161Term: HIV infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2008-004631-37-Outside-EU/EEATibotec Pharmaceuticals12
进行中（未招募）
1 期
A Phase II, open-label trial, to evaluate pharmacokinetics, safety, tolerability and antiviral activity of DRV/rtv once daily in treatment-naïve HIV 1 infected adolescents aged between 12 and < 18 years.This trial will be referred to as DIONE.Estudio en Fase II, abierto, para evaluar la farmacocinética, seguridad, tolerabilidad y actividad antiviral de DRV/rtv una vez al día en adolescentes infectados por VIH-1 de entre 12 y < 18 años de edad no tratados. Nos referiremos a este estudio como DIONE. - DIONEHIV-1VIH-1MedDRA version: 9.1Level: LLTClassification code 10020161Term: HIV infectionEUCTR2008-004631-37-ESTibotec Pharmaceuticals12